文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胃肠道间质瘤的分子特征与免疫微环境：治疗策略的靶点

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies.

作者信息

Yu Yang, Yu Mengdie, Luo Lijie, Zhang Zijing, Zeng Haiping, Chen Yan, Lin Zeyu, Chen Mengnan, Wang Wei

机构信息

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong, China.

Guangzhou KingMed Diagnostics Group Co., Ltd., Guangzhou, Guangdong, China.

出版信息

Front Oncol. 2024 Jul 12;14:1405727. doi: 10.3389/fonc.2024.1405727. eCollection 2024.

DOI:10.3389/fonc.2024.1405727
PMID:39070147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11272528/
Abstract

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours, arising mainly from the interstitial cells of Cajal (ICCs) of the gastrointestinal tract. As radiotherapy and chemotherapy are generally ineffective for GISTs, the current primary treatment is surgical resection. However, surgical resection is not choice for most patients. Therefore, new therapeutic strategies are urgently needed. Targeted therapy, represented by tyrosine kinase inhibitors (TKIs), and immunotherapy, represented by immune checkpoint inhibitor therapies and chimeric antigen receptor T-cell immunotherapy (CAR-T), offer new therapeutic options in GISTs and have shown promising treatment responses. In this review, we summarize the molecular classification and immune microenvironment of GISTs and discuss the corresponding targeted therapy and immunotherapy options. This updated knowledge may provide more options for future therapeutic strategies and applications in GISTs.

摘要

胃肠道间质瘤（GISTs）是最常见的间充质肿瘤，主要起源于胃肠道的 Cajal 间质细胞（ICC）。由于放疗和化疗对 GISTs 通常无效，目前的主要治疗方法是手术切除。然而，手术切除并非大多数患者的选择。因此，迫切需要新的治疗策略。以酪氨酸激酶抑制剂（TKIs）为代表的靶向治疗以及以免疫检查点抑制剂疗法和嵌合抗原受体 T 细胞免疫疗法（CAR-T）为代表的免疫治疗，为 GISTs 提供了新的治疗选择，并已显示出有前景的治疗反应。在本综述中，我们总结了 GISTs 的分子分类和免疫微环境，并讨论了相应的靶向治疗和免疫治疗选择。这些更新的知识可能为 GISTs 未来的治疗策略和应用提供更多选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/e87381471abe/fonc-14-1405727-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/77f0ac636ca2/fonc-14-1405727-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/9e400d9a1cb5/fonc-14-1405727-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/81af8c2ec7ec/fonc-14-1405727-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/faca71f1fc0e/fonc-14-1405727-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/2581c9a7942c/fonc-14-1405727-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/e87381471abe/fonc-14-1405727-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/77f0ac636ca2/fonc-14-1405727-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/9e400d9a1cb5/fonc-14-1405727-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/81af8c2ec7ec/fonc-14-1405727-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/faca71f1fc0e/fonc-14-1405727-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/2581c9a7942c/fonc-14-1405727-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e95a/11272528/e87381471abe/fonc-14-1405727-g006.jpg

相似文献

[1]
Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies.

Front Oncol. 2024-7-12

[2]
Current research and treatment for gastrointestinal stromal tumors.

World J Gastroenterol. 2017-7-21

[3]
[Immunotherapy of Gastrointestinal Stromal Tumors].

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019-10-30

[4]
Recent advances in the management of gastrointestinal stromal tumor.

World J Clin Cases. 2020-8-6

[5]
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers.

Mol Cancer. 2023-4-18

[6]
Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.

Drugs. 2003

[7]
Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.

Int J Mol Sci. 2022-6-15

[8]
Ripretinib for the treatment of advanced gastrointestinal stromal tumor.

Therap Adv Gastroenterol. 2021-4-15

[9]
Targeted therapy of gastrointestinal stromal tumours.

World J Gastrointest Surg. 2016-5-27

[10]
Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.

Int J Mol Sci. 2021-1-6

本文引用的文献

[1]
Ferroptosis: principles and significance in health and disease.

J Hematol Oncol. 2024-6-6

[2]
Alkaliptosis induction counteracts paclitaxel-resistant ovarian cancer cells via ATP6V0D1-mediated ABCB1 inhibition.

Mol Carcinog. 2024-8

[3]
KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.

Expert Opin Investig Drugs. 2024-3

[4]
Cancer statistics, 2024.

CA Cancer J Clin. 2024

[5]
Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer.

Sci Transl Med. 2023-11

[6]
Cholesterol Metabolism in Cancer and Cell Death.

Antioxid Redox Signal. 2023-7

[7]
Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).

Clin Cancer Res. 2023-8-1

[8]
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers.

Mol Cancer. 2023-4-18

[9]
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.

Nat Immunol. 2023-6

[10]
Autophagy-Dependent Ferroptosis in Cancer.

Antioxid Redox Signal. 2023-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索